Nuchal translucency screening in triplets: Down syndrome risk calculation taking account of between‐fetus correlations

Abstract

Fetus-specific Down syndrome risks in triplets should be calculated using its own NT value and that in the other fetuses, chorionicity, and method of conception.

Evolution of gender options in multiple pregnancy management

“…Many groups have reported on the variable efficacy and additional limitations of screening tests in multiples as there is commonly confusion as to which fetus an abnormal screening test is attributable. [9][10][11][12][13] We, and a small number of other groups who developed and have extensive experience in chorionic villus sampling (CVS) in both singletons and multiples, began to routinely offer CVS prior to reduction in the late 1990s, which we believe offers a significant opportunity to improve the likelihood of healthy families for these patients. [14][15][16] Because of the advent of prenatal diagnosis techniques with the development of amniocentesis and ultrasound 40 years ago and CVS 30 years ago, their use (abuse) merely for the identification of gender with termination of normal females was a consistent although minor component of cases in the United States and many Western European countries.…”

“…This is still true for most FR providers. Many groups have reported on the variable efficacy and additional limitations of screening tests in multiples as there is commonly confusion as to which fetus an abnormal screening test is attributable . We, and a small number of other groups who developed and have extensive experience in chorionic villus sampling (CVS) in both singletons and multiples, began to routinely offer CVS prior to reduction in the late 1990s, which we believe offers a significant opportunity to improve the likelihood of healthy families for these patients …”